person · Reporting owner

HASTINGS DAVID C

Disclosed activity across 6 companies

Tapewire entity: 34527
SEC CIK: 0001237401

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Arbutus Biopharma CorpABUS · Entity 4953	Chief Financial Officer	February 14, 2025	February 19, 2025
Notable Labs, Ltd.VBLT · Entity 87239	Director	January 01, 2023	January 04, 2023
SCYNEXIS INCSCYX · Entity 7194	Director	June 26, 2026	June 30, 2026
Trevi Therapeutics, Inc.TRVI · Entity 4387	Chief Financial Officer	January 08, 2026	January 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Arbutus Biopharma Corp

Report date February 14, 2025 · Filed February 19, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	249,824	Reported balance After 2025-02-14 transaction · row 1 1 source row Row 1 · 2025-02-14 · Grant · Acquired 90,100 · Balance 249,824 F1: Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.29 · Expires 2035-02-14	Direct	365,800	Reported balance After 2025-02-14 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-02-14 · Grant · Acquired 365,800 · Balance 365,800 F2: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F3: This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.

F2: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.

F3: This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.

Notable Labs, Ltd.

Report date January 01, 2023 · Filed January 04, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.90 · Expires 2038-01-02	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-01-01 · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · Balance Not disclosed F1: These options were granted under the Issuer's Employee Share Ownership and Option Plan (2014) (the "2014 Plan") and are fully vested and exercisable.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2038-12-17	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-01-01 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F1: These options were granted under the Issuer's Employee Share Ownership and Option Plan (2014) (the "2014 Plan") and are fully vested and exercisable.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2039-12-19	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-01-01 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F2: These options were granted on 12/19/19 under the 2014 Plan, with 25% of the shares underlying these options vesting on December 19, 2020 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2040-12-08	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-01-01 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance Not disclosed F3: These options were granted on 12/08/20 under the 2014 Plan, with 25% of the shares underlying these options vesting on December 8, 2021 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.31 · Expires 2041-12-07	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-01-01 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance Not disclosed F4: These options were granted on 12/07/21 under the 2014 Plan and vest over two years commencing on the grant date such that 50% vest on the first anniversary of the date of grant and the remainder vest quarterly thereafter for one year such that they are vested in full on the two-year anniversary of the grant date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.12 · Expires 2042-01-02	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-01-01 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance Not disclosed F5: These options were granted on 01/02/22 under the 2014 Plan and vest over three years commencing on the grant date such that 50% vest on the first anniversary of the date of grant and the remainder vest quarterly thereafter for one year such that they are vested in full on the two-year anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: These options were granted under the Issuer's Employee Share Ownership and Option Plan (2014) (the "2014 Plan") and are fully vested and exercisable.

F2: These options were granted on 12/19/19 under the 2014 Plan, with 25% of the shares underlying these options vesting on December 19, 2020 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date.

F3: These options were granted on 12/08/20 under the 2014 Plan, with 25% of the shares underlying these options vesting on December 8, 2021 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date.

F4: These options were granted on 12/07/21 under the 2014 Plan and vest over two years commencing on the grant date such that 50% vest on the first anniversary of the date of grant and the remainder vest quarterly thereafter for one year such that they are vested in full on the two-year anniversary of the grant date.

F5: These options were granted on 01/02/22 under the 2014 Plan and vest over three years commencing on the grant date such that 50% vest on the first anniversary of the date of grant and the remainder vest quarterly thereafter for one year such that they are vested in full on the two-year anniversary of the grant date.

SCYNEXIS INC

Report date June 26, 2026 · Filed June 30, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	11,522	Reported balance After 2026-06-26 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-06-26 · Grant · Acquired 2,875 · Balance 11,522 F1: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date. F2: On May 29, 2026, the common stock of the Issuer underwent a 1-for-8 reverse stock split (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2036-06-25	Direct	2,875	Reported balance After 2026-06-26 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-26 · Grant · Acquired 2,875 · Balance 2,875 F3: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: One-hundred percent (100%) of the shares subject to the restricted stock unit vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date.

F2: On May 29, 2026, the common stock of the Issuer underwent a 1-for-8 reverse stock split (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.

F3: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant, provided that the non-employee director is providing continuous services on the applicable vesting date.

Trevi Therapeutics, Inc.

Report date January 08, 2026 · Filed January 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.21 · Expires 2036-01-07	Direct	375,000	Reported balance After 2026-01-08 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-08 · Grant · Acquired 375,000 · Balance 375,000 F1: This option was granted on January 8, 2026. The 375,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on January 8, 2027 and as to the remaining 75% of the shares in equal monthly installments thereafter through January 8, 2030.

Filing footnotes · ownership attribution and instrument terms

F1: This option was granted on January 8, 2026. The 375,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on January 8, 2027 and as to the remaining 75% of the shares in equal monthly installments thereafter through January 8, 2030.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Entasis Therapeutics Holdings Inc.

Report date July 07, 2022 · Filed July 11, 2022

Section 16 reporting ended · disclosed 2022-07-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-07-07 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2022-07-07 · Other · Disposed 22,000 · Balance 0 F1: Disposed of to Innoviva Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. ("Innoviva"), and Merger Sub (the "Merger Agreement"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the "Offer Price").
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2022-07-11 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2022-07-11 · Disposition to issuer · Disposed 27,500 · Balance 0 F2: Each Issuer restricted stock unit that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the "Merger") became effective (the "Effective Time") was deemed vested and converted into the right to receive a cash payment equal to the per share Merger consideration of $2.20.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.44	Direct	Reported balance After 2022-07-11 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-07-11 · Other · Disposed 26,583 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.98	Direct	Reported balance After 2022-07-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-07-11 · Other · Disposed 11,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of to Innoviva Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated May 23, 2022, by and between the Issuer, Innoviva, Inc. ("Innoviva"), and Merger Sub (the "Merger Agreement"), completed a tender offer to acquire all of the issued and outstanding shares of the Issuer's common stock (other than those shares owned by Innoviva and Merger Sub) at a purchase price of $2.20 per share (the "Offer Price").

F2: Each Issuer restricted stock unit that was outstanding immediately prior to the date and time at which the merger of Merger Sub with and into the Issuer (the "Merger") became effective (the "Effective Time") was deemed vested and converted into the right to receive a cash payment equal to the per share Merger consideration of $2.20.

F3: Pursuant to the Merger Agreement, at the Effective Time, each Company stock option with a per share exercise price less than the Offer Price, whether or not vested, was terminated and cancelled, and the holder thereof will receive the Offer Price less any applicable per share exercise price for each share subject to such award, pursuant to the terms set forth in the Merger Agreement. Each Company stock option with a per share exercise price equal to or greater than the Offer Price was cancelled immediately prior to the Effective Time, with no consideration payable.

Unilife Corp

Report date January 26, 2017 · Filed January 30, 2017

Section 16 reporting ended · disclosed 2017-01-30. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.53 · Expires 2027-01-26	Direct	150,000	Reported balance After 2017-01-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2017-01-26 · Grant · Acquired 150,000 · Balance 150,000 F1: The option vests in installments as follows: 37,500 shares on January 26, 2018; 37,500 shares on January 26, 2019; and 75,000 shares on January 26, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in installments as follows: 37,500 shares on January 26, 2018; 37,500 shares on January 26, 2019; and 75,000 shares on January 26, 2020.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 03, 2017 Filed Jan 5, 2017 23:16 UTC	SCYNEXIS INC SCYX · Entity 7194	GrantStock Option (right to buy) · Derivative	14,499	$0.00 Strike: $3.40	$0.00	Disclosure SEC source: 0001628280-17-000107 · wf-form4_148365815249164.xml · derivative · entry 1 HASTINGS DAVID C · CIK 0001237401 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,499 Underlying: Common Stock · 14,499 shares Expires 2027-01-03 F1 · derivative.exercise_date: One-hundred percent (100%) of the shares subject to the option vest on the first anniversary of the date of grant; provided, that the non-employee director is providing continuous services on the applicable vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.